TERMINATION AGREEMENTTermination Agreement • February 22nd, 2012 • Exelixis Inc • Services-commercial physical & biological research
THIS TERMINATION AGREEMENT (this “Termination Agreement”) is made and entered into as of December 22, 2011 (the “Termination Date”) by and between EXELIXIS, INC., a Delaware corporation having an address at 170 Harbor Way, P.O. Box 511, South San Francisco, California 94083-0511 (“Exelixis”), and SANOFI (formerly known as SANOFI-AVENTIS), a French company, having an address at 174, Avenue de France, 75013 Paris, France (“Sanofi”). Exelixis and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE LICENSE AGREEMENT between MERCK SHARP & DOHME CORP. and EXELIXIS, INC.Exclusive License Agreement • February 22nd, 2012 • Exelixis Inc • Services-commercial physical & biological research
THIS AGREEMENT is effective as of December 21, 2011 (the “Effective Date”) between Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“MERCK”), and Exelixis, Inc., a corporation organized and existing under the laws of Delaware (“EXELIXIS”).
